Loading
MAIA Biotechnology, Inc. is a clinical-stage biotech firm dedicated to discovering, developing, and commercializing treatments for various cancers, with a primary focus on non-small cell lung cancer. The company's leading experimental compound, THIO, is an investigational drug candidate that utilizes a unique dual mechanism by targeting telomeres and stimulating an immune response. Established in 2018, the enterprise maintains its headquarters in Chicago, Illinois.
Previous close
$1.22
+$0.07 · +6.09%
Regular session · ET · Market data may be delayed.
MAIA Biotechnology, Inc. is a clinical-stage biotech firm dedicated to discovering, developing, and commercializing treatments for various cancers, with a primary focus on non-small cell lung cancer. The company's leading experimental compound, THIO, is an investigational drug candidate that utilizes a unique dual mechanism by targeting telomeres and stimulating an immune response. Established in 2018, the enterprise maintains its headquarters in Chicago, Illinois.
Day range
Current $1.22
52-week range
Current $1.22
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
50
Fair Value
Sentiment
56
Mixed
Risk
63
High Risk
Momentum
45
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
MAIA Biotechnology, Inc. is a clinical-stage biotech firm dedicated to discovering, developing, and commercializing treatments for various cancers, with a primary focus on non-small cell lung cancer. The company's leading experimental compound, THIO, is an investigational drug candidate that utilizes a unique dual mechanism by targeting telomeres and stimulating an immune response. Established in 2018, the enterprise maintains its headquarters in Chicago, Illinois.
Day range
Current $1.22
52-week range
Current $1.22
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 14.55B USD | 10.01M USD | 11.11M USD | 8.93M USD | 3.45M USD |
| Selling, general, and administrative | 9.72B USD | 6.95M USD | 9.07M USD | 6.14M USD | 4.29M USD |
| Operating expenses | 24.27M USD | 16.96M USD | 20.18M USD | 16.18M USD | 7.79M USD |
| Interest income | 313.95K USD | 318.37K USD | 27.63K USD | 1.87K USD | 2.01K USD |
| Interest expense | — | 57 USD | — | 6.97K USD | 827.54K USD |
| Operating income | −24.27M USD | −16.96M USD | −20.18M USD | −16.18M USD | −7.79M USD |
| Net income | −22.4M USD | −23.25M USD | −19.77M USD | −15.77M USD | −12.5M USD |
Company facts updated Oct 10, 2026.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI2.2M0.00%2.3T USD0.03%$381.94+0.63%
Vanguard Extended Market ETFVXF875.23K0.00%95.4B USD0.05%$235+0.80%
iShares Micro-Cap ETFIWC194.86K0.01%1.32B USD0.60%$183+0.11%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM90K0.08%116.88M USD0.73%$15.9402+0.25%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
